vilazodone VIIBRYD

Class: SPARI/​Phenylpiperazine-2-benzofurancarboxamide
FDA Indications: MDD
Off-Label Use: Anxiety
Forms: 10, 20, 40mg tablet
Dose Range: 20-40 mg/day
Starting: Start with 10 mg qd x7 days, followed by 20 mg qd x7 days, then ↑ to 40 mg qd. Should be taken with food!

NAMI drug fact sheet

Contraindications: Concomitant use of MAOIs
Serious Side Effects: Serotonin syndrome; ↑ risk of SI in children and young adults; may impair platelet aggregation; SIADH
Side Effects: headache, diarrhea, nausea, dizziness, insomnia, abnormal dreams, hyperhidrosis, sexual dysfunction
1° MOA: Serotonin partial agonist and reuptake inhibitor
2° MOA: 5-HT1A receptor partial agonist
Target: SERT, 5HT1A
t½: 25 (20-30)° TMAX: 4-5°
Substrate of: 3A4; 2D6, 2C19
Inhibits: ∅ ; Induces:
Active Metabolites:
  • - DO NOT CO-PRESCRIBE WITH MAOIs (need a 14-day washout period)
  • - 3A4 inhibitors can ↑ levels; likewise, 3A4 inducers can ↓ levels
  • - AUC ↓ ~50% if not taken with food
  • - preferentially occupies 5HT1A autoreceptor vs the postsynaptic receptor, which has been theorized to accelerate and augment the clinical effects of SSRI
  • - Clinical trials showed significant antidepressant efficacy with an onset of effect in 1 week, unlike other antidepressants
  • - exhibits dose-proportional linear pharmacokinetics
  • - minimal sexual dysfunction
Special Populations

Category C—There are no adequate and well-controlled studies in pregnant women

There are no clinical data regarding the effect on lactation and nursing

There were no pharmacokinetic differences for vilazodone in patients >65

Mild to severe renal impairment does not affect the clearance.

Mild to severe hepatic impairment does not affect the clearance.


Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated February 29 2024 20:54:18. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.